SubHero Banner
Text

Oxtellar XR® (oxcarbazepine) – Expanded indication

December 14, 2018 - Supernus Pharmaceuticals announced the FDA approval of Oxtellar XR (oxcarbazepine), for the treatment of partial-onset seizures in patients 6 years of age and older.

Download PDF